Citi Reiterates Sell Rating on Hims and Hers (HIMS), PT $30, 'we do think that this will be a slight headwind to HIMS'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Drops Third Note on Hims and Hers (HIMS) Inside 20 Hours: 'HIMS is now offering discounts on its bundles, effectively passing through the price discount'
May 22, 2025 2:50 PM EDT(Updated - May 22, 2025 2:52 PM EDT)
Citi analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "In response to Novo lowering the cash pay price of Wegovy to $199 for the first month... More
Citi Reiterates Sell Rating on Hims and Hers (HIMS), Comments on Novo's Wegovy Price Promo: 'We see this as another potential headwind for HIMS
May 22, 2025 11:34 AM EDTCiti analyst Daniel Grosslight reiterated a Sell rating and $30.00 price target on Hims and Hers (NYSE: HIMS)
The analyst comments "With the end of 503B bulk compounding of commercially available semaglutide today, NovoCare announced a promotion offering cash pay access to Wegovy for $199... More
